Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 443,707 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the sale, the chief executive officer owned 174,144 shares in the company, valued at $5,790,288. The trade was a 71.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Stock Up 2.5%

NASDAQ:NAMS opened at $31.18 on Thursday. The company has a market cap of $3.58 billion, a PE ratio of -18.02 and a beta of 0.04. The business’s 50 day moving average is $33.79 and its two-hundred day moving average is $33.14. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. As a group, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NAMS. The Goldman Sachs Group lifted their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Wall Street Zen cut NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Needham & Company LLC raised their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Guggenheim upped their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $47.10.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NAMS. Farther Finance Advisors LLC raised its stake in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares in the last quarter. Mather Group LLC. bought a new position in shares of NewAmsterdam Pharma in the third quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of NewAmsterdam Pharma during the third quarter valued at $30,000. Wells Fargo & Company MN raised its stake in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. Finally, Navalign LLC bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at about $46,000. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.